Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.

14 There was also a nonsignificant trend toward improvement in DFS ( P = .077) and overall survival ( P = .067) in hormone receptor–negative, HER2-negative tumors. 14 Here, we report the long-term outcomes, at 12.1 years, for this original cohort of 2716 patients and report, for the first time, the outcomes of a second cohort of 578 patients also treated as a part of S0221 according to the revised protocol who were assigned to treatment with 4 cycles of every 2 weeks AC but randomly assigned to either 12 weeks of therapy with paclitaxel weekly or every 2 weeks.

also in 5,406 other papers